Sclerosis News and Research

RSS

"Nanovaccine" reverses diabetes

A new study, published online April 8 by Cell Press in the journal Immunity, describes a unique therapeutic "nanovaccine" that successfully reverses diabetes in a mouse model of the disease. In addition to providing new insight into diabetes, the research also reveals an aspect of the pathogenesis of the autoimmune response that may provide a therapeutic strategy for multiple autoimmune disorders.

9 Apr 2010

Nanotechnology-based vaccine cures mice with type 1 diabetes

Using a sophisticated nanotechnology-based "vaccine," researchers were able to successfully cure mice with type 1 diabetes and slow the onset of the disease in mice at risk for the disease. The study, co-funded by the Juvenile Diabetes Research Foundation, provides new and important insights into understanding how to stop the immune attack that causes type 1 diabetes, and could even have implications for other autoimmune diseases.

9 Apr 2010

Smoking may increase risk of MS in people who have established risk factors for MS

A new study shows that smoking may increase the risk of multiple sclerosis in people who also have specific established risk factors for MS. The research is found in the April 7, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology.

8 Apr 2010

Role of beta defensins in development of chronic inflammatory response in the brain

Researchers at the Case Western Reserve University School of Dental Medicine and School of Medicine will look for evidence within the brain for human beta defensin peptide function-proteins important to the peripheral body's natural defense system against infection from the outside environment.

8 Apr 2010

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Teva Pharmaceutical Industries Ltd. today announced that several new studies supporting the company's innovative central nervous system portfolio will be presented at the 62nd American Academy of Neurology Annual Meeting in Toronto, April 10-17, 2010.

8 Apr 2010

Women living in northeastern U.S. more likely to develop RA: Study

Women living in the northeastern United States are more likely to develop rheumatoid arthritis, suggesting a link between the autoimmune disease and vitamin D deficiency, says a new study led by a Boston University School of Public Health researcher.

8 Apr 2010

Study demonstrates potential ability of Chronix serum DNA assays in diagnosis of breast cancer

Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis (MS). Chronix Biomedical uses proprietary technology to identify disease-specific genetic fingerprints based on the circulating DNA that is released into the bloodstream by damaged and dying cells.

7 Apr 2010

Defective protein responsible for SCA5 disease cuts synaptic terminals and snarls traffic inside neurons

The neurodegenerative disease spinocerebellar ataxia type 5 (SCA5) damages nerve cells in two ways. University of Minnesota researchers now report that the defective protein responsible for the disease cuts the number of synaptic terminals and snarls traffic inside neurons.

7 Apr 2010

Opexa Therapeutics to present data from Phase 2b TERMS clinical trial for Tovaxin at 62nd AAN meeting

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company has been selected to present key efficacy data at the upcoming American Academy of Neurology (AAN) 62nd Annual Meeting to be held in Toronto, Canada.

7 Apr 2010

New study shows utility of Chronix Biomedical's serum DNA tests in MS

Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis. Chronix Biomedical uses proprietary technology to identify disease-specific genetic fingerprints based on the circulating DNA that is released into the bloodstream by damaged and dying cells.

6 Apr 2010

Dalfampridine drug for multiple sclerosis now available in the U.S.

A drug whose clinical benefit in treating multiple sclerosis was discovered at Rush University Medical Center was approved by the Food and Drug Administration on January 22 and is now available in the U.S.

6 Apr 2010

Rebirth of the cursed drug Thalidomide

Thalidomide was once a dreaded name in the Pharmaceutical industry. It was initially marketed in some European countries nearly 5 decades back as a sedative and after millions of pregnant women took it for morning sickness it had devastating results on the babies. The babies were born with flippers instead of limbs a condition known as phocomelia. Since then it has been under strict control.

5 Apr 2010

Opexa Therapeutics to discuss on personalized medicine for treatment of MS

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis, announced today that the company will participate in a panel discussion on Personalized Medicine for the Treatment of Multiple Sclerosis on April 7, 2010.

5 Apr 2010

Is relief round the corner for multiple sclerosis patients in the form of bee stings?

A recent development can raise the hopes of many sufferers of Multiple Sclerosis (MS) – a dreaded, debilitating, fatal nerve disorder. Charity worker Sami Chugg, 45, claims to have overcome her condition after being stung by bees.

5 Apr 2010

New report questions the kinetics of T cell receptors

T cell receptors are among the most important molecules in the immune system because of their role in recognizing the antigens that signal such threats as viruses and cancer. The receptors must also distinguish these threats from the body's own cells to avoid triggering an unwanted immune system response.

5 Apr 2010

Clinical utility and pharmacological action of MN-166 in treatment of MS

MediciNova, Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today reported that this week's issue of Neurology includes two articles related to the potential clinical utility and unique pharmacological action of MN-166 in treating multiple sclerosis (MS).

3 Apr 2010

Kinetics of T cell receptors: New findings could lead to reevaluation of earlier conclusions

3 Apr 2010

DNA resources coupled to EMR systems hold potential as valuable tools for clinical research

A new study reveals an exciting potential benefit of the rapidly accumulating databases of health care information, the ability to make unprecedented links between genomic data and clinical medicine. The research, published by Cell Press in the April issue of the American Journal of Human Genetics, supports the idea that large scale DNA databanks linked to electronic medical record (EMR) systems provide a valuable platform for discovering, assessing and validating associations between genes and diseases.

2 Apr 2010

Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that new data from the company's multiple sclerosis portfolio of approved and investigational treatments will be presented at the 62nd Annual Meeting of the American Academy of Neurology taking place April 10 to 17, in Toronto, Canada.

1 Apr 2010

Metabolon awarded U.S. patents for metabolomics methods

Metabolon, Inc., the leader in global metabolism through biomarker discovery and analysis, announced today the grant of US Patent 7,682,783 and US Patent 7,682,784 entitled "Methods for Drug Discovery, Disease Treatment and Diagnosis Using Metabolomics". The USPTO awarded the patents to Metabolon on March 23, 2010. The issued claims in the new patents are for uses of metabolomics to identify diagnostic biomarkers for depression and schizophrenia by profiling classes of metabolites in a sample.

1 Apr 2010

Sclerosis News and Research

"Nanovaccine" reverses diabetes

Nanotechnology-based vaccine cures mice with type 1 diabetes

Smoking may increase risk of MS in people who have established risk factors for MS

Role of beta defensins in development of chronic inflammatory response in the brain

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Women living in northeastern U.S. more likely to develop RA: Study

Study demonstrates potential ability of Chronix serum DNA assays in diagnosis of breast cancer

Defective protein responsible for SCA5 disease cuts synaptic terminals and snarls traffic inside neurons

Opexa Therapeutics to present data from Phase 2b TERMS clinical trial for Tovaxin at 62nd AAN meeting

New study shows utility of Chronix Biomedical's serum DNA tests in MS

Dalfampridine drug for multiple sclerosis now available in the U.S.

Rebirth of the cursed drug Thalidomide

Opexa Therapeutics to discuss on personalized medicine for treatment of MS

Is relief round the corner for multiple sclerosis patients in the form of bee stings?

New report questions the kinetics of T cell receptors

Clinical utility and pharmacological action of MN-166 in treatment of MS

Kinetics of T cell receptors: New findings could lead to reevaluation of earlier conclusions

DNA resources coupled to EMR systems hold potential as valuable tools for clinical research

Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting

Metabolon awarded U.S. patents for metabolomics methods

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News